Lead for stimulating the baroreceptors in the pulmonary artery

Information

  • Patent Grant
  • 8024050
  • Patent Number
    8,024,050
  • Date Filed
    Wednesday, December 24, 2003
    20 years ago
  • Date Issued
    Tuesday, September 20, 2011
    13 years ago
Abstract
An apparatus includes a flexible lead body extending from a proximal end to a distal end, an expandable electrode coupled proximate the distal end, the expandable electrode having an expanded diameter dimensioned to abut a wall of a pulmonary artery, and an implantable pulse generator electrically coupled to the expandable electrode. The expandable electrode includes a plurality of electrode zones. The implantable pulse generator is adapted to deliver a baroreflex stimulation signal to a baroreceptor in the pulmonary artery via the electrode.
Description
CROSS REFERENCE TO RELATED APPLICATIONS

The following commonly assigned U.S. patent applications are related, are all filed on the same date as the present application and are all herein incorporated by reference in their entirety: “Baroreflex Stimulation System to Reduce Hypertension,” Ser. No. 10/746,134, now issued as U.S. Pat. No. 7,643,875; and “Stimulation Lead for Stimulating the Baroreceptors in the Pulmonary Artery,” Ser. No. 10/746,852.


FIELD

This application relates generally to implantable medical devices and, more particularly, to systems, devices and methods for reducing hypertension using baroreceptor stimulation.


BACKGROUND

Medical leads have a distal end having one or more electrodes and a proximal end having a terminal that is coupled to a pulse generator. Electrical therapy is delivered from the pulse generator to the body via the electrode.


Hypertension is a cause of heart disease and other related cardiac co-morbidities. Hypertension occurs when blood vessels constrict. As a result, the heart works harder to maintain flow at a higher blood pressure, which can contribute to heart failure. Many patients who suffer from hypertension do not respond to treatment, such as treatments related to lifestyle changes and hypertension drugs.


A pressoreceptive region is capable of sensing changes in pressure, such as changes in blood pressure. Pressoreceptor regions are referred to herein as baroreceptors, which generally include any sensors of pressure changes. For example, baroreceptors include afferent nerves and further include sensory nerve endings that are sensitive to the stretching of the wall that results from increased blood pressure from within, and function as the receptor of a central reflex mechanism that tends to reduce the pressure. Baroreflex functions as a negative feedback system, and relates to a reflex mechanism triggered by stimulation of a baroreceptor. Increased pressure stretches blood vessels, which in turn activate baroreceptors in the vessel walls. Activation of baroreceptors naturally occurs through internal pressure and stretching of the arterial wall, causing baroreflex inhibition of sympathetic nerve activity (SNA) and a reduction in systemic arterial pressure. An increase in baroreceptor activity induces a reduction of SNA, which reduces blood pressure by decreasing peripheral vascular resistance.


The general concept of stimulating afferent nerve trunks leading from baroreceptors is known. For example, direct electrical stimulation has been applied to the vagal nerve and carotid sinus using nerve cuffs. Research has indicated that electrical stimulation of the carotid sinus nerve can result in reduction of experimental hypertension, and that direct electrical stimulation to the pressoreceptive regions of the carotid sinus itself brings about reflex reduction in experimental hypertension.


What is needed is a less invasive technique for providing long-term electrical stimulation of the baroreflex.


SUMMARY

One aspect includes a flexible lead body extending from a proximal end to a distal end and having an expandable electrode coupled proximate the distal end of the lead body. The expandable electrode has an expanded diameter dimensioned to abut a wall of a pulmonary artery. The expandable electrode includes a plurality of electrode zones. An implantable pulse generator is electrically coupled to the expandable electrode and is adapted to deliver a baroreflex stimulation signal to a baroreceptor in the pulmonary artery via the expandable electrode.


One aspect includes a method. The method includes implanting an expandable electrode within a pulmonary artery such that an outer surface of the expandable electrode abuts a wall of the pulmonary artery, and delivering a baroreflex stimulation signal to a baroreceptor in the pulmonary artery via the electrode.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 shows a lead and pulse generator, in accordance with one embodiment.



FIG. 2 shows details of a heart.



FIG. 3 shows the lead of FIG. 1 implanted in a heart, in accordance with one embodiment.



FIG. 4 shows a lead having an expandable electrode in accordance with one embodiment.



FIG. 5 shows the lead of FIG. 4 with the electrode in an expanded configuration.



FIG. 6 shows an expandable electrode in accordance with one embodiment.



FIG. 7 shows a side view of a lead in accordance with one embodiment.





DETAILED DESCRIPTION

The following detailed description and accompanying drawings show specific embodiments in which the present invention may be practiced. These embodiments are described in sufficient detail to enable those skilled in the art to practice the invention. Other embodiments may be utilized and structural changes may be made without departing from the scope of the present invention.


A brief discussion of hypertension and the physiology related to baroreceptors is provided to assist the reader with understanding this disclosure. This brief discussion introduces hypertension, the autonomic nervous system, and baroreflex.


Hypertension is a cause of heart disease and other related cardiac co-morbidities. Hypertension generally relates to high blood pressure, such as a transitory or sustained elevation of systemic arterial blood pressure to a level that is likely to induce cardiovascular damage or other adverse consequences. Hypertension has been arbitrarily defined as a systolic blood pressure above 140 mm Hg or a diastolic blood pressure above 90 mm Hg. Hypertension occurs when blood vessels constrict. As a result, the heart works harder to maintain flow at a higher blood pressure. Consequences of uncontrolled hypertension include, but are not limited to, retinal vascular disease and stroke, left ventricular hypertrophy and failure, myocardial infarction, dissecting aneurysm, and renovascular disease.


The automatic nervous system (ANS) regulates “involuntary” organs, while the contraction of voluntary (skeletal) muscles is controlled by somatic motor nerves. Examples of involuntary organs include respiratory and digestive organs, and also include blood vessels and the heart. Often, the ANS functions in an involuntary, reflexive manner to regulate glands, to regulate muscles in the skin, eye, stomach, intestines and bladder, and to regulate cardiac muscle and the muscle around blood vessels, for example.


The ANS includes, but is not limited to, the sympathetic nervous system and the parasympathetic nervous system. The sympathetic nervous system is affiliated with stress and the “fight or flight response” to emergencies. Among other effects, the “fight or flight response” increases blood pressure and heart rate to increase skeletal muscle blood flow, and decreases digestion to provide the energy for “fighting or fleeing.” The parasympathetic nervous system is affiliated with relaxation and the “rest and digest response” which, among other effects, decreases blood pressure and heart rate, and increases digestion to conserve energy. The ANS maintains normal internal function and works with the somatic nervous system.


The subject matter of this disclosure generally refers to the effects that the ANS has on the heart rate and blood pressure, including vasodilation and vasoconstriction. The heart rate and force is increased when the sympathetic nervous system is stimulated, and is decreased when the sympathetic nervous system is inhibited (e.g. when the parasympathetic nervous system is stimulated).


Baroreflex is a reflex triggered by stimulation of a baroreceptor. A baroreceptor includes any sensor of pressure changes, such as sensory nerve endings in the wall of the auricles of the heart, cardiac fat pads, vena cava, aortic arch and carotid sinus, that is sensitive to stretching of the wall resulting from increased pressure from within, and that functions as the receptor of the central reflex mechanism that tends to reduce that pressure. Additionally, a baroreceptor includes afferent nerve trunks, such as the vagus, aortic and carotid nerves, leading from the sensory nerve endings. Stimulating baroreceptors inhibits sympathetic nerve activity (stimulates the parasympathetic nervous system) and reduces systemic arterial pressure by decreasing peripheral vascular resistance. Baroreceptors are naturally stimulated by internal pressure and the stretching of the arterial wall.


Some aspects of the present subject matter locally and directly stimulate specific nerve endings in arterial walls rather than stimulate afferent nerve trunks in an effort to stimulate a desire response (e.g. reduced hypertension) while reducing the undesired effects of indiscriminate stimulation of the nervous system. For example, some embodiments stimulate baroreceptor sites in the pulmonary artery. Some embodiments of the present subject matter involve stimulating baroreceptor sites in the aorta.



FIG. 1 shows a lead 100 according to one embodiment. Lead 100 includes a flexible lead body 110 extending from a proximal end 115 to a distal end 120. An expandable electrode 130 is coupled proximate the distal end 120 of lead body 110. As will be discussed below, electrode 130 is adapted to deliver stimulation to baroreceptors in the pulmonary artery. For example, the expandable electrode 130 can have an expanded diameter dimensioned to abut a wall of a pulmonary artery to hold the electrode in place without any active fixation.


Lead 100 is coupled to an implantable pulse generator 140. Lead 100 includes conductors, such as coiled conductors that electrically couple pulse generator 140 to expandable electrode 130. Accordingly, implantable pulse generator 140 can deliver a baroreflex stimulation signal to a baroreceptor in the pulmonary artery via the electrode 130. The lead further includes outer insulation to insulate the conductor. The system can include a unipolar system with the case acting as an electrode or a bipolar system with a pulse between two distally located electrodes.


In one embodiment, pulse generator 140 includes hardware, circuitry and software to perform NS functions. Some embodiments can also perform an AHT function. Pulse generator includes controller circuitry 142. The controller circuitry 142 is capable of being implemented using hardware, software, and combinations of hardware and software. For example, according to various embodiments, the controller circuitry 142 includes a processor to perform instructions embedded in a memory to perform functions associated with NS therapy such as AHT therapy. In one example, the pulse generator delivers a pulse train having a frequency of between 10 to 150 hertz via the electrode.



FIG. 2 shows a representation of a portion of a heart 200. Heart 200 includes an aortic arch 203 and a pulmonary artery 204. Pulmonary artery 204 includes a plurality of baroreceptors 206. A lead, such as lead 100 (FIG. 1), is capable of being intravascularly inserted through a peripheral vein and through the tricuspid valve into the right ventricle of the heart (not expressly shown in the figure) similar to a cardiac pacemaker lead, and continue from the right ventricle through the pulmonary valve 208 into the pulmonary artery 204.


A portion of the pulmonary artery 204 and aorta arch 203 are proximate to each other. According to various aspects of the present subject matter, the baroreflex is stimulated in or around the pulmonary artery by at least one electrode intravascularly inserted into the pulmonary artery. Aspects of the present subject matter provide a relatively noninvasive surgical technique to implant a baroreceptor stimulator intravascularly into the pulmonary artery. The baroreceptors 206, for example, are sensitive to stretching of the wall resulting from increased pressure from within. Activation of these nerve endings reduce pressure.


As illustrated, the pulmonary artery 204 includes a number of baroreceptors 206, as generally indicated by the dark areas. Furthermore, a cluster of closely spaced baroreceptors 206B are situated near the attachment of the ligamentum arteriosum 212. According to various embodiments of the present subject matter, a lead is inserted through a peripheral vein and threaded through the tricuspid valve into the right ventricle, and from the right ventricle through the pulmonary valve 208 and into the pulmonary artery 204 to simulate baroreceptors in and/or around the pulmonary artery. In various embodiments, for example, the lead is positioned in the artery to stimulate the cluster of baroreceptors 206B near the ligamentum arteriosum 212.


There are also baroreceptor fields in the aortic arch 203, near the ligamentum arteriosum 212, and in the trunk 220 of the pulmonary artery 204. Some embodiments position the lead in the pulmonary artery to stimulate baroreceptor sites in the aorta, possibly via the ligamentum arteriosum 212, or in the pulmonary trunk, or in either the right or left pulmonary arteries.



FIG. 3 shows expandable electrode 130 mounted in pulmonary artery 204, in accordance with one embodiment. In one embodiment, expandable electrode 130 is a stent-like structure including a mesh surface 302. The expandable electrode is designed to expand to abut the outer walls 304 of the pulmonary artery so as to passively fixate the lead and the electrode in place by frictional forces. In this example, the electrode is adapted to be located near the ligamentum arteriosum 212 of the left pulmonary artery 204.


Expandable electrode 130 can have various shapes and sizes. In one embodiment, the length to diameter ratio is smaller than in typical stents. For example, one embodiment includes a length of at least about 1 cm. Other examples can be up to 3 cm or greater. The diameter of the electrode 130 in its expanded orientation can range from about 10 mm to about 20 mm. Other embodiments can have a larger diameter. In general, the electrode is dimensioned to provide direct, low-voltage, high-frequency nerve stimulation.


In one embodiment, lead 100 can include a second electrode 312 located proximally from the expandable electrode 130. This electrode can be used for bradyarrhythmia therapy, tachyarrhythmia therapy, as a sensing electrode, or as a cathode for electrode 130.


In one example, electrode 130 is adapted to be chronically implanted in the pulmonary artery. For example, by passively mounting the electrode within the artery, no long-term damage is done to the artery.



FIGS. 4 and 5 show lead 100, in accordance with one embodiment. Lead 100 can include an inflatable balloon 402 that can be inflated once the electrode is positioned correctly. Inflating the balloon 402 expands the electrode 130 until the electrode abuts the walls of the artery, as discussed above.



FIG. 6 shows an expandable electrode 630, in accordance with one embodiment. Electrode 630 can be used in place of electrode 130 discussed above. Electrode 630 includes an outer surface 640 that can be at least partially masked so as to be electrically non-conductive. For example, electrode 630 has been marked off into zones A, B, and C. Zones A, B, and C can have varying sizes and shapes and the zones shown are an example. In one example, sections A and C can be electrically conductive and zone B is masked off. Alternatively, any of the sections or portions can be electrically insulated.


In one embodiment, none of sections A, B, or C is masked off and each is coupled to a separate conductor of lead 100 (FIG. 1). In this example, the user implants the electrode and then tests each zone separately to discover which gives the best baroreflex response. Then, the non-productive zones can be turned off, or used for sensing, for example.



FIG. 7 illustrates a baroreceptor stimulation lead 700 with an integrated pressure sensor 710 (IPS) and an expandable electrode 702, according to various embodiments of the present subject matter. In one example, lead 700 can include an IPS 710 with a baroreceptor stimulator electrode 712 to monitor changes in blood pressure, and thus to monitor the effect of the baroreceptor stimulation. In various embodiments, micro-electrical mechanical systems (MEMS) technology can be used to sense the blood pressure. Some sensor embodiments determine blood pressure based on a displacement of a membrane.


In one example use of lead 700, a system can include baroreceptor stimulation circuitry and sensor circuitry. The circuitry can be within pulse generator 140 (FIG. 1) or be a separate system communicating wirelessly with the pulse generator. One or more leads can be connected to the sensor circuitry and baroreceptor stimulation circuitry. The baroreceptor stimulation circuitry is used to apply electrical stimulation pulses to desired baroreceptors sites, such as baroreceptor sites in the pulmonary artery, through one or more stimulation electrodes, such as electrodes 702 or 712. The sensor circuitry is used to detect and process ANS nerve activity and/or surrogate parameters such as blood pressure, respiration and the like, to determine the ANS activity.


Lead 700, for example, is capable of being intravascularly introduced to stimulate a baroreceptor site, such as the baroreceptor sites in the pulmonary artery, aortic arch, or ligamentum arteriosum. One or more additional electrodes can be provided to pace and/or sense cardiac activity, such as that which may occur within the right ventricle with the sensor 710 located near baroreceptors in or near the pulmonary artery and programmed to stimulate and sense, either directly or indirectly through surrogate parameters, baroreflex activity.


To provide hypertension therapy according to one embodiment, a lead, such as lead 100, is intravascularly inserted through a peripheral vein and through the tricuspid valve into the right ventricle of the heart and then from the right ventricle through the pulmonary valve into the pulmonary artery. An electrode on the lead is fixated to a region of the pulmonary artery having one or more baroreceptors. One example passively fixates the electrode proximate the ligamentum arteriosum of the left pulmonary artery. In one embodiment, the pulse generator is designed to intermittently pace the baroreceptor with a low-voltage, high frequency pulse train. For example, the baroreceptor can be paced for about 5 to 10 seconds each minute at a voltage of about 0.1 volts to 10 volts and a frequency between about 10 Hz and 150 Hz. Some examples utilize a voltage between about 1 volt to about 10 volts.


As noted, further embodiments can include a sensor to monitor blood pressure. The sensor can sense a physiological parameter regarding an efficacy of the baroreflex therapy and provides a signal indicative of the efficacy of the baroreflex therapy. For example, a controller can be connected to a pulse generator to control the baroreflex stimulation signal and to the sensor to receive the signal indicative of the efficacy of the baroreflex therapy. In some examples, the pulse generator can be further adapted to generate a cardiac pacing signal, and the lead can include a second electrode to be positioned to deliver the cardiac pacing signal to capture the heart. The present expandable electrode allows for chronically indwelling, is easy to implant, and is safe and reliable.


In various embodiments of baroreceptor pacing according to the present subject matter, the system can deliver the pulse train intermittently with no sensing, or the system can be activated by the user when the user is at rest, or it can be activated by a timer to be periodically turned off and on, or it can be activated when the user goes to sleep, for example.


According to various embodiments, the stimulator circuitry and sensing circuitry of the present system can include one or more functions as described in the commonly assigned U.S. patent application filed on the same date as the present application and incorporated by reference in its entirety: “Baroreflex Stimulation System to Reduce Hypertension,” Ser. No. 10/746,134, filed on Dec. 24, 2003.


For example, various embodiments of the present subject matter relate to baroreflex stimulator systems. Such baroreflex stimulation systems are also referred to herein as neural stimulator (NS) devices or components. Examples of neural stimulators include anti-hypertension (AHT) devices or AHT components that are used to treat hypertension. Various embodiments of the present subject matter include stand-alone implantable baroreceptor stimulator systems, include implantable devices that have integrated NS and cardiac rhythm management (CRM) components, and include systems with at least one implantable NS device and an implantable CRM device capable of communicating with each other either wirelessly or through a wire lead connecting the implantable devices. Integrating NS and CRM functions that are either performed in the same or separate devices improves aspects of the NS therapy and cardiac therapy by allowing these therapies to work together intelligently.


Thus, various embodiments of the present subject matter provide an implantable NS device that automatically modulates baroreceptor stimulation using an IPS. Integrating the pressure sensor into the lead provides localized feedback for the stimulation. This localized sensing improves feedback control. For example, the integrated sensor can be used to compensate for inertia of the baroreflex such that the target is not continuously overshot. According to various embodiments, the device monitors pressure parameters such as mean arterial pressure, systolic pressure, diastolic pressure and the like. As mean arterial pressure increases or remains above a programmable target pressure, for example, the device stimulates baroreceptors at an increased rate to reduce blood pressure and control hypertension.


As mean arterial pressure decreases towards the target pressure, the device responds by reducing baroreceptor stimulation. In various embodiments, the algorithm takes into account the current metabolic state (cardiac demand) and adjusts neural stimulation accordingly. A NS device having an IPS is able to automatically modulate baroreceptor stimulation, which allows an implantable NS device to determine the level of hypertension in the patient and respond by delivering the appropriate level of therapy. However, it is noted that other sensors, including sensors that do not reside in an NS or neural stimulator device, can be used to provide close loop feedback control.


An aspect of the present subject matter relates to a chronically-implanted stimulation system specially designed to treat hypertension by monitoring blood pressure and stimulating baroreceptors to activate the baroreceptor reflex and inhibit sympathetic discharge from the vasomotor center. Baroreceptors are located in various anatomical locations such as the carotid sinus and the aortic arch. Other baroreceptor locations include the pulmonary artery, including the ligamentum arteriosum, and sites in the atrial and ventricular chambers. In various embodiments, the system is integrated into a pacemaker/defibrillator or other electrical stimulator system. Components of the system include a high-frequency pulse generator, sensors to monitor blood pressure or other pertinent physiological parameters, leads to apply electrical stimulation to baroreceptors, algorithms to determine the appropriate time to administer stimulation, and algorithms to manipulate data for display and patient management.


Various embodiments relates to a system that seeks to deliver electrically mediated NS therapy, such as AHT therapy, to patients. Various embodiments combine a “stand-alone” pulse generator with a minimally invasive, unipolar lead that directly stimulates baroreceptors in the vicinity of the heart, such as in the pulmonary artery. This embodiment is such that general medical practitioners lacking the skills of specialist can implant it. Various embodiments incorporate a simple implanted system that can sense parameters indicative of blood pressure. This system adjusts the therapeutic output (waveform amplitude, frequency, etc.) so as to maintain a desired quality of life. In various embodiments, an implanted system includes a pulse generating device and lead system, the stimulating electrode of which is positioned near endocardial baroreceptor tissues using transvenous implant technique(s).


Another embodiment includes a system that combines NS therapy with traditional bradyarrhythmia, tachyarrhythmia, and/or congestive heart failure (CHF) therapies. Some embodiments use an additional “baroreceptor lead” that emerges from the device header and is paced from a modified traditional pulse generating system. In another embodiment, a traditional CRM lead is modified to incorporate proximal electrodes that are naturally positioned near baroreceptor sites. With these leads, distal electrodes provide CRM therapy and proximal electrodes stimulate baroreceptors.


Various embodiments of the present subject matter relate to a method of sensing atrial activation and confining pulmonary artery stimulation to the atrial refractory period, preventing unintentional stimulation of nearby atrial tissue. An implantable baroreceptor stimulation device monitors atrial activation with an atrial sensing lead. A lead in the pulmonary artery stimulates baroreceptors in the vessel wall. However, instead of stimulating these baroreceptors continuously, the stimulation of baroreceptors in the pulmonary artery occurs during the atrial refractory period to avoid capturing nearby atrial myocardium, maintaining the intrinsic atrial rate and activation. Various embodiments of the present subject matter combine an implantable device for stimulating baroreceptors in the wall of the pulmonary artery with the capability for atrial sensing.


In some embodiments, the pulse generator can include a transceiver and associated circuitry for use to communicate with a programmer or another external or internal device. Various embodiments have wireless communication capabilities. For example, some transceiver embodiments use a telemetry coil to wirelessly communicate with a programmer or another external or internal device.


The above description is intended to be illustrative, and not restrictive. Many other embodiments will be apparent to those of skill in the art upon reviewing the above description. The scope of the invention should, therefore, be determined with reference to the appended claims, along with the full scope of equivalents to which such claims are entitled.

Claims
  • 1. An apparatus comprising: a flexible lead body extending from a proximal end to a distal end;an expandable electrode coupled proximate the distal end, the expandable electrode having a stent-like structure and an expanded diameter dimensioned to abut a wall of a pulmonary artery, the expandable electrode comprising a plurality of electrode zones, each zone individually coupled to a separate conductor of the lead body; andan implantable pulse generator electrically coupled to the expandable electrode via the conductors, wherein each of the electrode zones is tested to determine which zone delivers the best baroreflex response and at least one of the electrode zones is selected, and wherein the implantable pulse generator is programmed to deliver a baroreflex stimulation signal to a baroreceptor in the pulmonary artery via the at least one selected electrode zone of the expandable electrode, wherein the implantable pulse generator is programmed such that the signal is delivered for about 5 seconds to about 10 seconds each minute at a voltage of about 0.1 volts to about 10 volts and a frequency of about 10 Hz to 150 Hz.
  • 2. The apparatus of claim 1, wherein the expandable electrode includes a mesh surface.
  • 3. The apparatus of claim 1, wherein the expandable electrode expands to fix the lead body in place by frictional forces.
  • 4. The apparatus of claim 1, wherein the expandable electrode includes a length of at least about 1 cm.
  • 5. The apparatus of claim 1, wherein the expandable electrode includes an expanded diameter of about 10 to 20 mm.
  • 6. The apparatus of claim 1, wherein the expandable electrode includes at least a partially electrically insulated surface.
  • 7. The apparatus of claim 1, wherein the lead body includes a second electrode located proximally from the expandable electrode.
  • 8. The apparatus of claim 1, wherein the pulse generator delivers about a 10 hertz pulse train via the electrode.
  • 9. The apparatus of claim 1, wherein the expandable electrode is adapted to be chronically implanted in the pulmonary artery.
  • 10. The apparatus of claim 1, wherein the lead body further includes a sensor to monitor blood pressure.
  • 11. The apparatus of claim 1, wherein the expandable electrode is adapted to be located near a ligamentum arteriosum of the left pulmonary artery.
  • 12. The apparatus of claim 1, further including a sensor to sense a physiological parameter regarding an efficacy of the baroreflex stimulation and to provide a signal indicative of the efficacy of the baroreflex stimulation.
  • 13. The apparatus of claim 12, further including a controller connected to the pulse generator to control the baroreflex stimulation pulse and to the sensor to receive the signal indicative of the efficacy of the baroreflex stimulation.
  • 14. The apparatus of claim 1, wherein the lead body is adapted to be fed through a right ventricle and a pulmonary valve into the pulmonary artery to position the electrode in the pulmonary artery.
  • 15. The apparatus of claim 1, wherein the pulse generator is further adapted to generate a cardiac pacing signal, the lead body further including a second electrode to be positioned to deliver the cardiac pacing signal to capture the heart.
  • 16. The apparatus of claim 1, wherein the implantable pulse generator is programmed to deliver the baroreflex stimulation signal to the baroreceptor such that the stimulation signal causes a lowering of blood pressure.
  • 17. An apparatus comprising: a flexible lead body extending from a proximal end to a distal end;an expandable electrode coupled to the lead body, the expandable electrode comprising a plurality of electrode zones, each zone individually coupled to a separate conductor within the lead body; andan implantable pulse generator electrically coupled to the electrode via the separate conductors, wherein each zone can be tested separately to determine which zone delivers the best baroreflex response and at least one of the electrode zones is selected to deliver a baroreflex stimulation pulse to a baroreceptor in a pulmonary artery to produce a baroreflex response and the implantable pulse generator is programmed to deliver a baroreflex stimulation signal to the baroreceptor in the pulmonary artery via the at least one selected electrode zones.
  • 18. The apparatus of claim 17, wherein the expandable electrode comprises an expandable stent structure coupled to the lead body for passively fixating the expandable electrode in the pulmonary artery.
  • 19. The apparatus of claim 18, wherein the stent structure includes an expanded diameter dimensioned to abut a wall of a pulmonary artery.
  • 20. The apparatus of claim 19, wherein the expanded diameter is about 10 to 20 mm.
  • 21. The apparatus of claim 18, wherein the expandable stent structure expands to fix the lead body in place by frictional forces.
  • 22. The apparatus of claim 18, wherein the expandable stent structure includes a length of at least about 1 cm.
  • 23. The apparatus of claim 17, wherein the pulse generator delivers about a 10 hertz pulse train via the electrode.
  • 24. The apparatus of claim 17, wherein the implantable pulse generator is programmed to deliver the baroreflex stimulation signal to the baroreceptor such that the stimulation signal causes a lowering of blood pressure.
  • 25. The apparatus according to claim 17, wherein the implantable pulse generator is programmed such that the signal is delivered for about 5 seconds to about 10 seconds each minute at a voltage of about 0.1 volts to about 10 volts and a frequency of about 10 Hz to 150 Hz.
US Referenced Citations (380)
Number Name Date Kind
3421511 Schwartz et al. Jan 1969 A
3522811 Seymour et al. Aug 1970 A
3650277 Sjostrand et al. Mar 1972 A
4357946 Dutcher et al. Nov 1982 A
4397946 Imada et al. Aug 1983 A
4730619 Koning et al. Mar 1988 A
4770177 Schroeppel Sep 1988 A
4791931 Slate Dec 1988 A
4936304 Kresh et al. Jun 1990 A
4960129 dePaola et al. Oct 1990 A
5024222 Thacker Jun 1991 A
5052388 Sivula et al. Oct 1991 A
5111815 Mower May 1992 A
5190035 Salo et al. Mar 1993 A
5199428 Obel et al. Apr 1993 A
5203326 Collins Apr 1993 A
5243980 Mehra Sep 1993 A
5318592 Schaldach Jun 1994 A
5324316 Schulman et al. Jun 1994 A
5330507 Schwartz Jul 1994 A
5334221 Bardy Aug 1994 A
5356425 Bardy et al. Oct 1994 A
5374282 Nichols et al. Dec 1994 A
5403351 Saksena Apr 1995 A
5409009 Olson Apr 1995 A
5411531 Hill et al. May 1995 A
5437285 Verrier et al. Aug 1995 A
5507784 Hill et al. Apr 1996 A
5513644 McClure et al. May 1996 A
5522854 Ideker et al. Jun 1996 A
5540730 Terry, Jr. et al. Jul 1996 A
5562711 Yerich et al. Oct 1996 A
5578061 Stroetmann et al. Nov 1996 A
5593430 Renger Jan 1997 A
5651378 Matheny et al. Jul 1997 A
5658318 Stroetmann et al. Aug 1997 A
5662689 Elsberry et al. Sep 1997 A
5690681 Geddes et al. Nov 1997 A
5700282 Zabara Dec 1997 A
5707400 Terry, Jr. et al. Jan 1998 A
5749900 Schroeppel et al. May 1998 A
5792187 Adams Aug 1998 A
5817131 Elsberry et al. Oct 1998 A
5902324 Thompson et al. May 1999 A
5913876 Taylor et al. Jun 1999 A
5916239 Geddes et al. Jun 1999 A
6006122 Smits Dec 1999 A
6006134 Hill et al. Dec 1999 A
6035233 Schroeppel et al. Mar 2000 A
6058331 King May 2000 A
6073048 Kieval et al. Jun 2000 A
6076014 Alt Jun 2000 A
6104956 Naritoku et al. Aug 2000 A
6134470 Hartlaub Oct 2000 A
6141590 Renirie et al. Oct 2000 A
6144878 Schroeppel et al. Nov 2000 A
6161042 Hartley et al. Dec 2000 A
6161048 Sluijter et al. Dec 2000 A
6164284 Schulman et al. Dec 2000 A
6169918 Haefner et al. Jan 2001 B1
6178349 Kieval Jan 2001 B1
6181966 Nigam Jan 2001 B1
6240314 Plicchi et al. May 2001 B1
6240316 Richmond et al. May 2001 B1
6266564 Hill et al. Jul 2001 B1
6272377 Sweeney et al. Aug 2001 B1
6285907 Kramer et al. Sep 2001 B1
6292695 Webster, Jr. et al. Sep 2001 B1
6292703 Meier et al. Sep 2001 B1
6308104 Taylor et al. Oct 2001 B1
6341236 Osorio et al. Jan 2002 B1
6349233 Adams Feb 2002 B1
6371922 Baumann et al. Apr 2002 B1
6381499 Taylor et al. Apr 2002 B1
6400982 Sweeney et al. Jun 2002 B2
6405079 Ansarinia Jun 2002 B1
6411845 Mower Jun 2002 B1
6421557 Meyer Jul 2002 B1
6438423 Rezai et al. Aug 2002 B1
6442424 Ben-Haim et al. Aug 2002 B1
6447443 Keogh et al. Sep 2002 B1
6449507 Hill et al. Sep 2002 B1
6473644 Terry, Jr. et al. Oct 2002 B1
6477418 Plicchi et al. Nov 2002 B2
6487442 Wood Nov 2002 B1
6487446 Hill et al. Nov 2002 B1
6487450 Chen et al. Nov 2002 B1
6493585 Plicchi et al. Dec 2002 B2
6511500 Rahme Jan 2003 B1
6522926 Kieval et al. Feb 2003 B1
6532388 Hill et al. Mar 2003 B1
6542774 Hill et al. Apr 2003 B2
6564096 Mest May 2003 B2
6571121 Schroeppel et al. May 2003 B2
6571122 Schroeppel et al. May 2003 B2
6574512 Zhang et al. Jun 2003 B1
6584362 Scheiner et al. Jun 2003 B1
6600954 Cohen et al. Jul 2003 B2
6610713 Tracey Aug 2003 B2
6611713 Schauerte Aug 2003 B2
6622041 Terry, Jr. et al. Sep 2003 B2
6628987 Hill et al. Sep 2003 B1
6662052 Sarwal et al. Dec 2003 B1
6668191 Boveja Dec 2003 B1
6684105 Cohen et al. Jan 2004 B2
6690971 Schauerte et al. Feb 2004 B2
6718203 Weiner et al. Apr 2004 B2
6718207 Connelly Apr 2004 B2
6718208 Hill et al. Apr 2004 B2
6735471 Hill et al. May 2004 B2
6763268 MacDonald et al. Jul 2004 B2
6778854 Puskas Aug 2004 B2
6788970 Park et al. Sep 2004 B1
6799069 Weiner et al. Sep 2004 B2
6804561 Stover Oct 2004 B2
RE38654 Hill et al. Nov 2004 E
6838471 Tracey Jan 2005 B2
6839592 Grandjean Jan 2005 B2
6845267 Harrison et al. Jan 2005 B2
RE38705 Hill et al. Feb 2005 E
6882886 Witte et al. Apr 2005 B1
6885888 Rezai Apr 2005 B2
6904318 Hill et al. Jun 2005 B2
6912419 Hill et al. Jun 2005 B2
6922585 Zhou et al. Jul 2005 B2
6928320 King Aug 2005 B2
6928326 Levine Aug 2005 B1
6934583 Weinberg et al. Aug 2005 B2
6937896 Kroll Aug 2005 B1
6942622 Turcott Sep 2005 B1
6985774 Kieval et al. Jan 2006 B2
7025730 Cho et al. Apr 2006 B2
7058450 Struble et al. Jun 2006 B2
7092755 Florio Aug 2006 B2
7136704 Schulman Nov 2006 B2
7139607 Shelchuk Nov 2006 B1
7155284 Whitehurst et al. Dec 2006 B1
7158832 Kieval et al. Jan 2007 B2
7167756 Torgerson et al. Jan 2007 B1
7194313 Libbus Mar 2007 B2
7245967 Shelchuk Jul 2007 B1
7260431 Libbus et al. Aug 2007 B2
7277761 Shelchuk Oct 2007 B2
7294334 Michal et al. Nov 2007 B1
7299086 McCabe et al. Nov 2007 B2
7321793 Ben Ezra et al. Jan 2008 B2
7333854 Brewer et al. Feb 2008 B1
7403819 Shelchuk et al. Jul 2008 B1
7460906 Libbus Dec 2008 B2
7480532 Kieval et al. Jan 2009 B2
7486991 Libbus et al. Feb 2009 B2
7493161 Libbus et al. Feb 2009 B2
7499748 Moffitt et al. Mar 2009 B2
7509166 Libbus Mar 2009 B2
7542800 Libbus et al. Jun 2009 B2
7548780 Libbus et al. Jun 2009 B2
7551958 Libbus et al. Jun 2009 B2
7555341 Moffitt et al. Jun 2009 B2
7561923 Libbus et al. Jul 2009 B2
7570999 Libbus et al. Aug 2009 B2
7572228 Wolinsky et al. Aug 2009 B2
7584004 Caparso et al. Sep 2009 B2
7587238 Moffitt et al. Sep 2009 B2
7643875 Hiel, Jr. et al. Jan 2010 B2
7647114 Libbus Jan 2010 B2
7657312 Pastore et al. Feb 2010 B2
7706884 Libbus Apr 2010 B2
7734348 Zhang et al. Jun 2010 B2
7765000 Zhang et al. Jul 2010 B2
7769450 Libbus et al. Aug 2010 B2
7783353 Libbus et al. Aug 2010 B2
7869881 Libbus et al. Jan 2011 B2
20010020136 Sweeney et al. Sep 2001 A1
20020004670 Florio et al. Jan 2002 A1
20020010493 Poezevara et al. Jan 2002 A1
20020016344 Tracey Feb 2002 A1
20020016550 Sweeney et al. Feb 2002 A1
20020026221 Hill et al. Feb 2002 A1
20020026222 Schauerte et al. Feb 2002 A1
20020026228 Schauerte Feb 2002 A1
20020032468 Hill et al. Mar 2002 A1
20020042637 Stover Apr 2002 A1
20020058877 Baumann et al. May 2002 A1
20020068875 Schroeppel et al. Jun 2002 A1
20020072776 Osorio et al. Jun 2002 A1
20020077670 Archer et al. Jun 2002 A1
20020082661 Plicchi et al. Jun 2002 A1
20020091415 Lovett et al. Jul 2002 A1
20020095139 Keogh et al. Jul 2002 A1
20020107553 Hill et al. Aug 2002 A1
20020107557 Edell et al. Aug 2002 A1
20020116030 Rezai Aug 2002 A1
20020120304 Mest Aug 2002 A1
20020123769 Panken et al. Sep 2002 A1
20020138109 Keogh et al. Sep 2002 A1
20020143369 Hill et al. Oct 2002 A1
20020161410 Kramer et al. Oct 2002 A1
20020165586 Hill et al. Nov 2002 A1
20020183237 Puskas Dec 2002 A1
20020183793 Struble et al. Dec 2002 A1
20020188325 Hill et al. Dec 2002 A1
20020188326 Zheng et al. Dec 2002 A1
20020193843 Hill et al. Dec 2002 A1
20020198570 Puskas Dec 2002 A1
20020198571 Puskas Dec 2002 A1
20030003052 Hampton Jan 2003 A1
20030004549 Hill et al. Jan 2003 A1
20030018368 Ansarinia Jan 2003 A1
20030023279 Spinelli et al. Jan 2003 A1
20030036773 Whitehurst et al. Feb 2003 A1
20030040774 Terry et al. Feb 2003 A1
20030045909 Gross et al. Mar 2003 A1
20030045914 Cohen et al. Mar 2003 A1
20030060848 Keival et al. Mar 2003 A1
20030060857 Perrson et al. Mar 2003 A1
20030060858 Kieval et al. Mar 2003 A1
20030074039 Puskas Apr 2003 A1
20030078623 Weinberg et al. Apr 2003 A1
20030078629 Chen Apr 2003 A1
20030100924 Foreman et al. May 2003 A1
20030105493 Salo Jun 2003 A1
20030114905 Kuzma Jun 2003 A1
20030125770 Fuimaono et al. Jul 2003 A1
20030149450 Mayberg Aug 2003 A1
20030158584 Cates Aug 2003 A1
20030176818 Schuler et al. Sep 2003 A1
20030181951 Cates Sep 2003 A1
20030191403 Zhou et al. Oct 2003 A1
20030191404 Klein Oct 2003 A1
20030195578 Perron et al. Oct 2003 A1
20030212440 Boveja Nov 2003 A1
20030212445 Weinberg Nov 2003 A1
20030216790 Hill et al. Nov 2003 A1
20030216792 Levin et al. Nov 2003 A1
20030229380 Adams et al. Dec 2003 A1
20030236558 Whitehurst et al. Dec 2003 A1
20040010303 Bolea Jan 2004 A1
20040015204 Whitehurst et al. Jan 2004 A1
20040015205 Whitehurst et al. Jan 2004 A1
20040019364 Kieval et al. Jan 2004 A1
20040024422 Hill et al. Feb 2004 A1
20040030362 Hill et al. Feb 2004 A1
20040038857 Tracey Feb 2004 A1
20040048795 Ivanova et al. Mar 2004 A1
20040049120 Cao et al. Mar 2004 A1
20040049235 Deno et al. Mar 2004 A1
20040054381 Pastore et al. Mar 2004 A1
20040059383 Puskas Mar 2004 A1
20040068299 Laske et al. Apr 2004 A1
20040088009 Degroot May 2004 A1
20040088015 Casavant et al. May 2004 A1
20040111118 Hill et al. Jun 2004 A1
20040116970 Girouard et al. Jun 2004 A1
20040122496 Zhang et al. Jun 2004 A1
20040122497 Zhang et al. Jun 2004 A1
20040122498 Zhang et al. Jun 2004 A1
20040127942 Yomtov et al. Jul 2004 A1
20040127947 Kim et al. Jul 2004 A1
20040133248 Frei et al. Jul 2004 A1
20040138721 Osorio et al. Jul 2004 A1
20040162584 Hill et al. Aug 2004 A1
20040162594 King Aug 2004 A1
20040172074 Yoshihito Sep 2004 A1
20040172075 Shafer et al. Sep 2004 A1
20040172094 Cohen et al. Sep 2004 A1
20040186517 Hill et al. Sep 2004 A1
20040186531 Jahns et al. Sep 2004 A1
20040193231 David et al. Sep 2004 A1
20040199209 Hill et al. Oct 2004 A1
20040199210 Shelchuk Oct 2004 A1
20040215289 Fukui Oct 2004 A1
20040220621 Zhou et al. Nov 2004 A1
20040243182 Cohen et al. Dec 2004 A1
20040243206 Tadlock Dec 2004 A1
20040249416 Yun et al. Dec 2004 A1
20040249429 Tadlock Dec 2004 A1
20040254612 Ben Ezra et al. Dec 2004 A1
20040254616 Rossing et al. Dec 2004 A1
20040260374 Zhang et al. Dec 2004 A1
20040260375 Zhang et al. Dec 2004 A1
20050010263 Schauerte Jan 2005 A1
20050015129 Mische Jan 2005 A1
20050021092 Yun et al. Jan 2005 A1
20050059897 Snell et al. Mar 2005 A1
20050065553 Ben Ezra et al. Mar 2005 A1
20050065555 Er Mar 2005 A1
20050065562 Rezai Mar 2005 A1
20050065573 Rezai Mar 2005 A1
20050065575 Dobak Mar 2005 A1
20050075701 Shafer Apr 2005 A1
20050075702 Shafer Apr 2005 A1
20050085864 Schulman et al. Apr 2005 A1
20050096705 Pastore et al. May 2005 A1
20050096707 Hill et al. May 2005 A1
20050125044 Tracey Jun 2005 A1
20050131467 Boveja Jun 2005 A1
20050143412 Puskas Jun 2005 A1
20050143779 Libbus Jun 2005 A1
20050143785 Libbus Jun 2005 A1
20050143787 Boveja et al. Jun 2005 A1
20050149126 Libbus Jul 2005 A1
20050149127 Libbus Jul 2005 A1
20050149128 Heil, Jr. et al. Jul 2005 A1
20050149129 Libbus et al. Jul 2005 A1
20050149130 Libbus Jul 2005 A1
20050149131 Libbus et al. Jul 2005 A1
20050149132 Libbus Jul 2005 A1
20050149133 Libbus et al. Jul 2005 A1
20050149143 Libbus et al. Jul 2005 A1
20050149148 King Jul 2005 A1
20050149155 Scheiner et al. Jul 2005 A1
20050149156 Libbus et al. Jul 2005 A1
20050154418 Kieval et al. Jul 2005 A1
20050182288 Zabara Aug 2005 A1
20050187584 Denker et al. Aug 2005 A1
20050187586 David et al. Aug 2005 A1
20050197600 Schuler et al. Sep 2005 A1
20050197675 David et al. Sep 2005 A1
20050222632 Obino Oct 2005 A1
20050251216 Hill et al. Nov 2005 A1
20050261741 Libbus et al. Nov 2005 A1
20060074453 Kieval et al. Apr 2006 A1
20060079945 Libbus Apr 2006 A1
20060089678 Shalev Apr 2006 A1
20060106428 Libbus et al. May 2006 A1
20060106429 Libbus et al. May 2006 A1
20060116737 Libbus Jun 2006 A1
20060122675 Libbus et al. Jun 2006 A1
20060134071 Ross et al. Jun 2006 A1
20060134079 Sih et al. Jun 2006 A1
20060136027 Westlund et al. Jun 2006 A1
20060136028 Ross et al. Jun 2006 A1
20060217772 Libbus et al. Sep 2006 A1
20060253156 Pastore et al. Nov 2006 A1
20060259107 Caparso et al. Nov 2006 A1
20060271115 Ben-Ezra et al. Nov 2006 A1
20060271118 Libbus et al. Nov 2006 A1
20060282131 Caparso et al. Dec 2006 A1
20070021790 Kieval et al. Jan 2007 A1
20070021792 Kieval et al. Jan 2007 A1
20070021796 Kieval et al. Jan 2007 A1
20070021797 Kieval et al. Jan 2007 A1
20070021798 Kieval et al. Jan 2007 A1
20070021799 Kieval et al. Jan 2007 A1
20070034261 Eichler Feb 2007 A1
20070038259 Kieval et al. Feb 2007 A1
20070038260 Kieval et al. Feb 2007 A1
20070038261 Kieval et al. Feb 2007 A1
20070038262 Kieval et al. Feb 2007 A1
20070060972 Kieval et al. Mar 2007 A1
20070067008 Scheiner et al. Mar 2007 A1
20070068260 Hong et al. Mar 2007 A1
20070093875 Chavan et al. Apr 2007 A1
20070142864 Libbus et al. Jun 2007 A1
20070142871 Libbus et al. Jun 2007 A1
20070167984 Kieval et al. Jul 2007 A1
20070191904 Libbus et al. Aug 2007 A1
20080021507 Libbus et al. Jan 2008 A1
20080086174 Libbus et al. Apr 2008 A1
20080125843 Ben-David et al. May 2008 A1
20080147140 Ternes et al. Jun 2008 A1
20080167694 Bolea et al. Jul 2008 A1
20080177350 Kieval et al. Jul 2008 A1
20080200960 Libbus Aug 2008 A1
20080228238 Libbus Sep 2008 A1
20090048641 Libbus Feb 2009 A1
20090132002 Kieval May 2009 A1
20090143834 Libbus Jun 2009 A1
20090143838 Libbus et al. Jun 2009 A1
20090198294 Rossing et al. Aug 2009 A1
20090306734 Moffitt Dec 2009 A1
20100076511 Heil, Jr. et al. Mar 2010 A1
20100106226 Libbus Apr 2010 A1
20100125307 Pastore et al. May 2010 A1
20100185255 Libbus Jul 2010 A1
20100222832 Zhang et al. Sep 2010 A1
20100274321 Libbus Oct 2010 A1
20100286740 Libbus et al. Nov 2010 A1
20100298898 Libbus Nov 2010 A1
20110082514 Libbus et al. Apr 2011 A1
Foreign Referenced Citations (45)
Number Date Country
0547734 Jun 1993 EP
1486232 Dec 2004 EP
1541193 Jun 2005 EP
1706177 Oct 2006 EP
1297991 Nov 1972 GB
49015438 Apr 1974 JP
05269210 Oct 1993 JP
2005519680 Jul 2005 JP
2005521489 Jul 2005 JP
WO-9216257 Oct 1992 WO
WO-9713550 Apr 1997 WO
WO-9740885 Nov 1997 WO
WO-0124876 Apr 2001 WO
WO-0176689 Oct 2001 WO
WO-0226318 Apr 2002 WO
WO-0226314 Apr 2002 WO
WO-0226318 Apr 2002 WO
WO-0226320 Apr 2002 WO
WO-0234327 May 2002 WO
WO-02085448 Oct 2002 WO
WO03011388 Feb 2003 WO
WO-03026741 Apr 2003 WO
WO-03041559 May 2003 WO
WO-03076008 Sep 2003 WO
WO-03082080 Oct 2003 WO
WO-03082080 Oct 2003 WO
WO-03082403 Oct 2003 WO
WO-03099373 Dec 2003 WO
WO-03099377 Dec 2003 WO
WO-2004012814 Feb 2004 WO
WO-2004084990 Oct 2004 WO
WO-2004084993 Oct 2004 WO
WO-2004103455 Dec 2004 WO
WO-2004105870 Dec 2004 WO
WO-2004110549 Dec 2004 WO
WO-2004110550 Dec 2004 WO
WO-2005018739 Mar 2005 WO
WO-2005042091 May 2005 WO
WO-2005053788 Jun 2005 WO
WO-2005063332 Jul 2005 WO
WO-2005065771 Jul 2005 WO
WO-2005113066 Dec 2005 WO
WO-2006031331 Mar 2006 WO
WO-2007078410 Jul 2007 WO
WO-2008063396 May 2008 WO
Related Publications (1)
Number Date Country
20050149156 A1 Jul 2005 US